{
    "info": {
        "nct_id": "NCT06100276",
        "official_title": "A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).",
        "inclusion_criteria": "* Confirmed clinical and genetic diagnosis of SOD1-mediated ALS (SOD1-ALS) experiencing signs and/or symptoms of lower motor neuron dysfunction (weakness, atrophy, cramps, fasciculations), with or without upper motor neuron symptoms (weakness, bring reflexes, spasticity).\n* ALSFRS-R score ≥ 25 at Screening.\n* Slow vital capacity (SVC) ≥50% of predicted normal value.\n* Capable of providing informed consent and complying with trial procedures, including: medically able to undergo lumbar puncture and has a responsible caregiver able to attend all clinic visit with the Participant.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.\n* Pathogenic repeat expansion in the C9orf72 gene\n* Any of the following prior or concomitant treatments:\n\n  * Any prior SOD1 suppression therapy with viral microRNA mediators\n  * Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.\n  * Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.\n  * Any prior administration of an AAV gene therapy.\n* Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed clinical and genetic diagnosis of SOD1-mediated ALS (SOD1-ALS) experiencing signs and/or symptoms of lower motor neuron dysfunction (weakness, atrophy, cramps, fasciculations), with or without upper motor neuron symptoms (weakness, bring reflexes, spasticity).",
            "criterions": [
                {
                    "exact_snippets": "Confirmed clinical and genetic diagnosis of SOD1-mediated ALS (SOD1-ALS)",
                    "criterion": "SOD1-mediated ALS diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "clinical",
                                "genetic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "experiencing signs and/or symptoms of lower motor neuron dysfunction (weakness, atrophy, cramps, fasciculations)",
                    "criterion": "lower motor neuron dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": [
                                "weakness",
                                "atrophy",
                                "cramps",
                                "fasciculations"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without upper motor neuron symptoms (weakness, bring reflexes, spasticity)",
                    "criterion": "upper motor neuron symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "optional"
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": [
                                "weakness",
                                "bring reflexes",
                                "spasticity"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ALSFRS-R score ≥ 25 at Screening.",
            "criterions": [
                {
                    "exact_snippets": "ALSFRS-R score ≥ 25 at Screening",
                    "criterion": "ALSFRS-R score",
                    "requirements": [
                        {
                            "requirement_type": "value at Screening",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Slow vital capacity (SVC) ≥50% of predicted normal value.",
            "criterions": [
                {
                    "exact_snippets": "Slow vital capacity (SVC) ≥50% of predicted normal value.",
                    "criterion": "slow vital capacity (SVC)",
                    "requirements": [
                        {
                            "requirement_type": "percentage of predicted normal value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Capable of providing informed consent and complying with trial procedures, including: medically able to undergo lumbar puncture and has a responsible caregiver able to attend all clinic visit with the Participant.",
            "criterions": [
                {
                    "exact_snippets": "Capable of providing informed consent",
                    "criterion": "informed consent capability",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "complying with trial procedures",
                    "criterion": "trial procedure compliance",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "medically able to undergo lumbar puncture",
                    "criterion": "lumbar puncture ability",
                    "requirements": [
                        {
                            "requirement_type": "medical ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has a responsible caregiver able to attend all clinic visit with the Participant",
                    "criterion": "responsible caregiver attendance",
                    "requirements": [
                        {
                            "requirement_type": "caregiver attendance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any of the following prior or concomitant treatments:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following prior or concomitant treatments",
                    "criterion": "prior or concomitant treatments",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™). Exception: Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment and if there were no previous tofersen-related SAEs or ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment.",
            "criterions": [
                {
                    "exact_snippets": "Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators such as tofersen (QALSODY™)",
                    "criterion": "prior SOD suppression therapy with ASO mediators",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who previously received tofersen may be enrolled if the last dose of tofersen was received at least 20 weeks prior to the first Screening assessment",
                    "criterion": "time since last tofersen dose",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no previous tofersen-related SAEs",
                    "criterion": "history of tofersen-related serious adverse events (SAEs)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "no ... ongoing tofersen-related adverse events that would increase the risk of receiving AMT-162, per Investigator judgment",
                    "criterion": "ongoing tofersen-related adverse events increasing risk of AMT-162",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression.",
            "criterions": [
                {
                    "exact_snippets": "riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®), and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or bioequivalents are allowed if dose is stable for 30 days prior to immunosuppression",
                    "criterion": "use of riluzole, edaravone, or sodium phenylbutyrate and taururosdiol combination (or bioequivalents)",
                    "requirements": [
                        {
                            "requirement_type": "dose stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing relative to immunosuppression",
                            "expected_value": "prior"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathogenic repeat expansion in the C9orf72 gene",
            "criterions": [
                {
                    "exact_snippets": "Pathogenic repeat expansion in the C9orf72 gene",
                    "criterion": "C9orf72 gene repeat expansion",
                    "requirements": [
                        {
                            "requirement_type": "pathogenicity",
                            "expected_value": "pathogenic"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162. After 6 months, Investigators and participants may decide to add new ALS medications or change existing ALS medications.",
            "criterions": [
                {
                    "exact_snippets": "Participants must be willing to forego new ALS treatments through at least 6 months after infusion of AMT-162.",
                    "criterion": "willingness to forego new ALS treatments",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior SOD1 suppression therapy with viral microRNA mediators",
            "criterions": [
                {
                    "exact_snippets": "Any prior SOD1 suppression therapy with viral microRNA mediators",
                    "criterion": "prior SOD1 suppression therapy with viral microRNA mediators",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.",
            "criterions": [
                {
                    "exact_snippets": "SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47",
                    "criterion": "SOD1 gene variant",
                    "requirements": [
                        {
                            "requirement_type": "pathogenicity",
                            "expected_value": [
                                "pathogenic",
                                "likely pathogenic"
                            ]
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 43,
                                        "unit": "amino acid position"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 47,
                                        "unit": "amino acid position"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior administration of an AAV gene therapy.",
            "criterions": [
                {
                    "exact_snippets": "Any prior administration of an AAV gene therapy",
                    "criterion": "AAV gene therapy administration",
                    "requirements": [
                        {
                            "requirement_type": "prior administration",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}